IDEXX LABORATORIES INC /DE Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31)
IDEXX LABORATORIES INC /DE (IDXX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) of 460.00% for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-04-20.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm · last filed 2012-04-20
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for the quarter ending 2012-03-31 was 460.00%, a 4.17% decline year-over-year.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for the quarter ending 2011-03-31 was 480.00%.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2011 was 480.00%, a 2.04% decline from fiscal 2010.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2010 was 490.00%, a 2.08% increase from fiscal 2009.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2009 was 480.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | 460.00% 10-Q · filed 2012-04-20 | |||
| 2011-12-31 | 480.00% 10-K · filed 2012-02-17 | |||
| 2011-09-30 | 480.00% 10-Q · filed 2011-10-21 | |||
| 2011-06-30 | 480.00% 10-Q · filed 2011-07-22 | |||
| 2011-03-31 | 480.00% 10-Q · filed 2012-04-20 | |||
| 2010-12-31 | 490.00% 10-K · filed 2012-02-17 | |||
| 2010-09-30 | 490.00% 10-Q · filed 2011-10-21 | |||
| 2010-06-30 | 490.00% 10-Q · filed 2011-07-22 | |||
| 2009-12-31 | 480.00% 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |